Danaher Beats Third-Quarter Earnings Forecasts and Raises Its Profit Outlook as Core Growth Excluding Respiratory Testing Reaches 5.5%

Danaher's third quarter cleared the bar its new chief executive needed it to clear — and the reported earnings line still needs its tax footnote read first.

Danaher reported third-quarter results on Wednesday, Oct. 21, with revenue of $6.55 billion, up 8.5% from a year earlier, and adjusted earnings of $2.11 a share, up 11.5%. The earnings figure beat the consensus estimate of $1.92 a share, and revenue was essentially in line with forecasts of about $6.56 billion, according to Seeking Alpha. The release was the first set of results under President and Chief Executive Julie Sawyer Montgomery, who assumed the roles on Oct. 1, and the company raised its full-year adjusted earnings guidance to $8.57 to $8.62 a share, from $8.45 to $8.60, against a consensus of $8.51.

The reported jump is mostly a tax story

Reported earnings look far stronger than the business performed, and the release itself shows why. Diluted earnings from continuing operations were $1.71 a share, up 34.5% from $1.27, and net earnings were $1.24 billion, including $1.21 billion from continuing operations and $28 million from discontinued operations. But income tax was a $75 million benefit in the quarter, against a $168 million expense a year earlier, because the results include $263 million of net discrete tax benefits related primarily to the release of reserves for uncertain tax positions resulting from audit settlements. The reconciliation makes the flattery explicit: discrete tax adjustments added $0.37 a share to reported earnings and are stripped out to reach the adjusted figure, which is why adjusted earnings grew 11.5% while the reported line grew 34.5%. Operating profit rose to $1.25 billion from $1.15 billion, on gross profit of $3.84 billion, selling, general and administrative expenses of $2.16 billion and research and development expenses of $433 million. Interest expense doubled to $135 million from $67 million, and the release's risk factors point to debt the company incurred to finance its acquisition of Masimo Corporation. Diluted shares were 706.8 million, down from 713.7 million.

Underneath, demand improved where it counts

The operating signal is cleaner than the reported profit line. Core revenue rose 3.0%, and core revenue excluding respiratory testing rose 5.5% — the acceleration Sawyer Montgomery pointed to when she said the company “delivered better-than-expected third quarter revenue, earnings and cash flow, and are encouraged by the improving trends we saw across our end markets.” Respiratory testing sales were about $400 million in the quarter, down from about $500 million a year earlier, so the shrinking pandemic-era business still masks stronger demand elsewhere. By segment, Biotechnology revenue rose 0.5% on a reported basis but core revenue rose 5.0%, Life Sciences revenue rose 4.0% with core growth of 4.5%, and Diagnostics revenue rose 17.0% — a reported figure that says less than it appears to, because acquisitions and divestitures contributed 16.5 percentage points of it, principally the Masimo acquisition, while Diagnostics core revenue rose just 0.5%, or 7.0% excluding respiratory testing.

A new core-growth definition arrived with the quarter

One definitional change deserves a reader's attention. Starting with the third-quarter Form 10-Q, Danaher is excluding tariff refunds to customers from core revenue growth — tariff refunds the company received for prior-period tariff payments and returns to its customers. The exclusion added 1.0 percentage point to total core growth in the quarter and 4.0 points in Biotechnology, which is part of why Biotechnology can show 0.5% total growth and 5.0% core growth in the same table. The change may be defensible, but it means this quarter's core figures are not measured quite the way earlier quarters were.

Cash generation did the confirming

Cash flow backed the earnings, with a caveat. Operating cash flow from continuing operations was $1.89 billion, up 13.5%, and free cash flow was $1.63 billion, up 19.0% from $1.37 billion. Conversion softened even as cash grew: free cash flow was 1.35 times continuing net earnings, down from 1.51 times, and operating cash flow conversion was 1.56 times, down from 1.83 times — a reminder that part of the earnings growth came from the tax benefit rather than from cash operations. Sawyer Montgomery framed the ambition in her first results release as making Danaher “the defining leader in Life Sciences and Diagnostics,” succeeding Rainer Blair, who stepped down from his executive duties and remains a senior advisor through March 31, 2027, under the succession plan first communicated on Aug. 3.

The raise is real but narrow

The guidance raise is genuine but tight: the new full-year range of $8.57 to $8.62 lifts the low end by 12 cents and the high end by 2 cents, and sits just above the $8.51 consensus Seeking Alpha carried. For the fourth quarter, Danaher expects core revenue excluding respiratory testing to grow 4.0% to 5.0%, with respiratory revenue an approximately 150-basis-point headwind leaving core growth of about 3.0%, and an adjusted operating margin of about 29.5%. Full-year core revenue is guided to about 2.5% growth, with core growth excluding respiratory testing at a mid-single-digit pace, and an effective tax rate of about 17%. Three things decide whether this print compounds: what management says on today's 8:00 a.m. Eastern call about end-market demand; whether the fourth-quarter respiratory headwind stays near 150 basis points; and how quickly the Masimo business is integrated against the debt taken on to buy it, with interest expense already doubled from a year earlier.